AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor (Ki = 0.78 nM) and CB2 receptor (Ki = 0.45 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 16x more potent.[3][4] Continuing the trend seen in other cannabinoids of this generation, such as AB-FUBINACA and AB-PINACA, it contains a valine amino acid amide residue as part of its structure, where older cannabinoids contained a naphthyl or adamantane residue.
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C20H28N4O2 |
Molar mass | 356.470 g·mol−1 |
3D model (JSmol) |
|
| |
|
There have been a number of reported cases of seizures, deaths, and psychotic episodes in relation to this synthetic cannabinoid.[5][6][7][8][9][10][11]
In 2015, AB-CHMINACA became a Schedule I controlled substance in the United States.[12]
AB-CHMINACA is an Anlage II controlled substance in Germany as of May 2015.[13]
As of October 2015 AB-CHMINACA is a controlled substance in China.[14]
AB-CHMINACA is illegal in Switzerland as of December 2015.[15]
AB-CHMINACA is an illegal substance in Russian Federation.